MAPT and Alzheimer disease: Serotonin 5-HT<sub>2B</sub> receptor levels are increased in the AD patient brain, and thus, treatment of AD animal models with the selective 5-HT<sub>2B</sub> receptor antagonist MW073 in prevention or disease stage paradigms attenuates Aβ- or tau-induced dysfunction.